Jemperli, a new cancer immunotherapy is attempting reimbursement listing in Korea.

According to industry sources, GSK Korea has recently submitted an application to list its PD-1 inhibitor Jemperli (dostarlimab) for reimbursement in Korea.

With the application, whether another treatment option may be released into the market remains to be seen.

Unlike other immunotherapies, Jemperli was first approved as a treatment for mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing chemotherapy regimen. Therefore, the company plans to first provide treatment opportunities to patients